Immatics Receives Funding to Develop T-Cell Receptor Based Immunotherapies
Immatics announced the completion of its Series E financing, raising $58 million.
The Series E funding was supported by existing investors including dievini Hopp Biotech holding,…
Read More...
Read More...
